文献速递甲状腺疾病

儿童甲状腺乳头状癌:术后不行辅助放射性碘治疗的结果

Pediatric Papillary Thyroid Carcinoma: Outcomes After Surgery Without Adjuvant Radioactive Iodine.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

这项在三级癌症中心开展的双向性研究纳入1990年至2021年诊断的93例1期儿童甲状腺乳头状癌患者,这些患者诊断后一年内有意未接受放射性碘治疗。中位随访5.5年后,91%的患者无病生存且未再治疗,9%出现持续或复发疾病;作者认为部分患儿即使有淋巴结转移也可能不需要治疗性放射性碘。

要点

  • 93例1期儿童甲状腺乳头状癌患者初始有意未行放射性碘治疗,中位随访5.5年。
  • 91%(85/93)保持无病且未再治疗,9%出现持续或复发疾病。
  • 仅4例最终接受放射性碘治疗,其中仅1例明确获益。

核心结论

  • 作者认为,经选择的儿童甲状腺乳头状癌患者,即使存在淋巴结转移,也可能不需要治疗性放射性碘,从而避免放射性碘的不必要风险,同时仍可获得该病公认的良好长期结局。

研究设计与样本

  • 这是一项在三级癌症中心开展的双向性研究,纳入1990年1月1日至2021年12月31日诊断的19岁以下1期甲状腺乳头状癌患者,这些患者在诊断后一年内有意未接受放射性碘治疗。
  • 共筛查490例甲状腺乳头状癌患者,确定93例符合条件者,诊断时中位年龄16岁,87%为女性,46例(49%)有颈部淋巴结转移。

主要发现

  • 初始处理包括甲状腺全切除±颈部清扫(69例,75%)、腺叶切除±颈部清扫(20例,21%)或异位甲状腺乳头状癌的Sistrunk手术(4例,4%)。
  • 中位随访5.5年(范围1-26年)后,85/93例(91%)保持无病且未再治疗。
  • 整个队列中9%发现持续(5例)或复发(3例)疾病。
  • 最终4例接受放射性碘治疗,其中仅1例明确获益;4例接受或计划了额外手术,其中2例末次随访时反应极佳。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Pediatric papillary thyroid carcinoma (PTC) is usually treated with total thyroidectomy followed by radioactive iodine (RAI). Recently, RAI has been used more selectively based on surgical pathology and postoperative dynamic risk stratification (DRS). OBJECTIVE: To describe patients with pediatric PTC not initially treated with RAI and their disease outcomes. METHODS: This was an ambispective study at a tertiary cancer center of patients < 19 years diagnosed from January 1, 1990, to December 31, 2021, with stage 1 PTC who intentionally were not treated with RAI within a year of diagnosis. We assessed clinical characteristics, management, and disease outcomes using DRS. RESULTS: Of 490 PTC patients, we identified 93 eligible patients (median age at diagnosis 16 years; 87% female), including 46 (49%) with cervical lymph node metastases. Initial management included total thyroidectomy ± neck dissection (n = 69, 75%), lobectomy ± neck dissection (n = 20, 21%), or a Sistrunk procedure for ectopic PTC (n = 4, 4%). After a median follow-up of 5.5 years (range 1-26), most patients (85/93; 91%) remained disease-free with no further therapy. Persistent (n = 5) or recurrent (n = 3) disease was found in 9% of the entire cohort. Four patients ultimately received RAI, of which only 1 clearly benefitted, and additional surgery was performed or planned in 4 patients, 2 of whom had an excellent response at last follow-up. CONCLUSION: Selected pediatric PTC patients, even those with lymph node metastases, may not require therapeutic 131I and can avoid the unnecessary risks of RAI while still benefitting from the excellent long-term outcomes that are well described for this disease.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Castellanos LE, Zafereo ME, Sturgis EM, et al. Pediatric Papillary Thyroid Carcinoma: Outcomes After Surgery Without Adjuvant Radioactive Iodine. J Clin Endocrinol Metab. 2025. PMID: 39163248. doi:10.1210/clinem/dgae576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。